Bemarituzumab

Last updated November 18, 2018

This article is being considered for deletion in accordance with Wikipedia's deletion policy.

Please share your thoughts on the matter at this article's entry on the Articles for deletion page.
Feel free to improve the article, but the article must not be blanked, and this notice must not be removed, until the discussion is closed. For more information, particularly on merging or moving the article during the discussion, read the guide to deletion.
Find sources: "Bemarituzumab" – news · newspapers · books · scholar · JSTOR

Bemarituzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	FGFR2
Clinical data
ATC code	none
Identifiers
CAS Number	1952272-74-0

Bemarituzumab (INN ^[1]) is a monoclonal antibody directed against fibroblast growth factor receptor 2b.^[2]^[3] It is being investigated for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma.

This drug is being developed by Five Prime Therapeutics, Zai Lab Limited. As of 2018^[update], bemarituzumab is undergoing Phase III trials.^[4]^[5]

References

↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
↑ "Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers". Business Wire. 2018-09-10.
↑ "Bemarituzumab". National Cancer Institute.
↑
↑

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab ^§ Ascrinvacumab ^§ Cixutumumab ^§ Conatumumab ^§ Daratumumab Drozitumab ^§ Duligotumab ^§ Dusigitumab ^§ Enfortumab vedotin ^† Enoticumab ^§ Figitumumab ^§ Ganitumab ^† Glembatumumab vedotin ^† Intetumumab ^§ Ipilimumab Iratumumab ^§ Istiratumab Icrucumab ^§ Lexatumumab ^§ Lucatumumab ^§ Mapatumumab ^§ Narnatumab ^§ Necitumumab Nesvacumab ^§ Ofatumumab Olaratumab ^† Panitumumab Patritumab ^§ Pritumumab ^§ Radretumab ^§ Ramucirumab Rilotumumab ^† Robatumumab ^§ Seribantumab ^§ Tarextumab ^§ Teprotumumab ^† Tovetumab ^§ Vantictumab ^§ Votumumab ^§ Zalutumumab ^† "-melu-" (melanoma) Flanvotumab ^§
Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Lilotomab Minretumomab Mitumomab Moxetumomab pasudotox ^† Naptumomab estafenatox Nofetumomab merpentan Pemtumomab ^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox
Chimeric ("-tuxi-")	Amatuximab ^§ Bavituximab ^§ Brentuximab vedotin Carotuximab ^† Cetuximab Derlotuximab biotin ^§ Dinutuximab Ensituximab ^§ Futuximab ^§ Girentuximab ^† Indatuximab ravtansine ^§ Isatuximab ^† Loncastuximab tesirine Margetuximab ^† Rituximab ^# Siltuximab Ublituximab ^† "-mexi-" (melanoma): Ecromeximab ^§
Humanized ("-tuzu-")	Abituzumab ^§ Alemtuzumab Bemarituzumab ^† Bevacizumab Bivatuzumab mertansine ^§ Brontictuzumab ^§ Cantuzumab mertansine ^§ Cantuzumab ravtansine ^§ Cirmtuzumab Citatuzumab bogatox ^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab ^§ Demcizumab ^§ Dalotuzumab ^§ Denintuzumab mafodotin ^§ Elotuzumab Emactuzumab ^§ Emibetuzumab ^§ Enoblituzumab ^§ Etaracizumab ^§ Farletuzumab ^§ Ficlatuzumab ^§ Flotetuzumab ^§ Gemtuzumab ozogamicin ^‡ Imgatuzumab ^§ Inotuzumab ozogamicin ^† Labetuzumab ^§ Lifastuzumab vedotin ^§ Lintuzumab ^§ Lorvotuzumab mertansine ^§ Lumretuzumab ^§ Matuzumab ^§ Milatuzumab ^§ Nimotuzumab ^† Obinutuzumab Ocaratuzumab ^§ Otlertuzumab ^§ Onartuzumab ^§ Oportuzumab monatox ^† Parsatuzumab ^§ Pertuzumab Pinatuzumab vedotin ^§ Polatuzumab vedotin ^† Rosmantuzumab Rovalpituzumab tesirine ^† Sacituzumab govitecan ^† Sibrotuzumab ^§ Simtuzumab ^§ Tacatuzumab tetraxetan ^§ Tigatuzumab ^§ Trastuzumab Tucotuzumab celmoleukin ^§ Vandortuzumab vedotin ^§ Vanucizumab ^§ Veltuzumab ^§ Vorsetuzumab mafodotin ^§ CBR96-doxorubicin immunoconjugate PankoMab "-gozu-" (ovarian tumor) Sofituzumab vedotin ^§
Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab ^§
Chimeric + humanized ("-tuxizu-")	Depatuxizumab mafodotin ^† Duvortuxizumab Ontuxizumab ^§

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.